YIR-819

CAS No. 1883372-86-8

YIR-819( YIR819 )

Catalog No. M12922 CAS No. 1883372-86-8

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    YIR-819
  • Note
    Research use only, not for human use.
  • Brief Description
    YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor.
  • Description
    YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM); A useful lead compound for the further development of HIV-1 entry inhibitors and could potentially be useful for co-administration with neutralizing antibodies for the treatment of HIV infection and AIDS.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    YIR819
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1883372-86-8
  • Formula Weight
    492.021
  • Molecular Formula
    C23H34ClN7O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N1-(4-chlorophenyl)-N2-(1-(2-(2-guanidinoacetamido)ethyl)-1-azaspiro[5.5]undecan-4-yl)oxalamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ohashi N, et al. ChemMedChem. 2016 Apr 19;11(8):940-6.
molnova catalog
related products
  • HIV-1 Rev 34-50

    HIV-1 Rev (34-50) is a 17-aa peptide derived from the Rev-responsive element (RRE)-binding domains of Rev in HIV-1, with anti-HIV-1 activity. HIV-1 Rev peptide is a one of the cell-penetrating peptides (CPPs) derived from HIV-1 Rev protein residue 34-50. It is a RNA binding peptideand has been used to deliver macromolecules into cells.

  • KM-023

    KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection.

  • Amprenavir

    A potent HIV-1 protease inhibitor with IC50 of 80 nM, has mean IC50 of 12 nM against 6 HIV clinical isolates.